{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:01:10Z","timestamp":1793995270689,"version":"4.8.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Mammalian targets of rapamycin inhibitors (mTORi) are considered second-line immunosuppression agents because of associated increases in rejection and impaired wound healing. Recent reports indicate mTORi have been linked to improved survival, decreased inflammatory response in pancreatitis, and antiproliferative and antiangiogenic activity. Mammalian targets of rapamycin inhibitors have not been extensively analyzed in pancreas transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with pancreas and kidney-pancreas transplants from 1987 to 2016 in the United Network for Organ Sharing database were analyzed (N = 25,837). Subjects were stratified into 2 groups: use of mTORi (n = 4174) and use of non\u2013mTORi-based immunosuppression (n = 21,663). The log-rank test compared survival rates. Univariate and multivariate Cox regression analyses assessed patient and graft survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mammalian targets of rapamycin inhibitors were associated with a 7% risk reduction in allograft failure (hazard ratio, 0.931;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006). Allograft survival rates were significantly different between mTORi versus non-mTORi (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001).The mTORi group showed a significantly higher patient survival rate 1, 3, 5, and 10 years posttransplant compared. Patient survival at 15 years was not significantly different.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of mTORi for immunosuppression in pancreas transplant is associated with improved allograft survival and early patient survival posttransplant (up to 10 years).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001322","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T18:02:47Z","timestamp":1557165767000},"page":"644-651","source":"Crossref","is-referenced-by-count":7,"title":["Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival"],"prefix":"10.1097","volume":"48","author":[{"given":"Eric J.","family":"Siskind","sequence":"first","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon T.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Emery","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Steen","sequence":"additional","affiliation":[{"name":"University of Toledo Transplant Center, Toledo, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Tran","sequence":"additional","affiliation":[{"name":"University of Toledo Transplant Center, Toledo, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Stodghill","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piper","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Inova Fairfax Medical Campus, Falls Church, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[{"name":"University of Toledo Transplant Center, Toledo, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2S Suppl 1","key":"bib1-20230822","first-page":"S30","article-title":"mTOR inhibition and clinical transplantation: pancreas and islet","volume":"102","year":"2018","journal-title":"Transplantation"},{"key":"bib2-20230822","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.transproceed.2004.12.072","article-title":"Pilot study of early corticosteroid elimination after pancreas transplantation","volume":"37","year":"2005","journal-title":"Transplant Proc"},{"key":"bib3-20230822","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00007890-200001270-00012","article-title":"Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression","volume":"69","year":"2000","journal-title":"Transplantation"},{"key":"bib4-20230822","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/TP.0b013e318188405f","article-title":"One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation","volume":"86","year":"2008","journal-title":"Transplantation"},{"key":"bib5-20230822","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/gerona\/glw090","article-title":"Rapamycin: an inhibiTOR of aging emerges from the soil of Easter Island","volume":"71","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"bib6-20230822","first-page":"4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","year":"2016","journal-title":"J Transplant"},{"key":"bib7-20230822","first-page":"74.abstract I-05","article-title":"Sirolimus versus mycophenolate mofetil in tacrolimus based primary simultaneous pancreas and kidney (SPK) transplantation: results of the EuroSPK 002 randomized trial","volume":"8","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"bib8-20230822","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1111\/j.1600-6143.2012.04235.x","article-title":"Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"bib9-20230822","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/ctr.12381","article-title":"Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation","volume":"28","year":"2014","journal-title":"Clin Transplant"},{"key":"bib10-20230822","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12967-014-0224-z","article-title":"Rapamycin protects kidney against ischemia reperfusion injury through recruitment of NKT cells","volume":"12","year":"2014","journal-title":"J Transl Med"},{"key":"bib11-20230822","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000348496","article-title":"Effects of everolimus on oxidative stress in kidney model of ischemia\/reperfusion injury","volume":"37","year":"2013","journal-title":"Am J Nephrol"},{"key":"bib12-20230822","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus","volume":"17","year":"2017","journal-title":"Am J Transplant"},{"key":"bib13-20230822","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.jacc.2009.08.031","article-title":"Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction","volume":"54","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"bib14-20230822","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.transproceed.2015.12.071","article-title":"Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression","volume":"48","year":"2016","journal-title":"Transplant Proc"},{"key":"bib15-20230822","doi-asserted-by":"crossref","first-page":"e13265","DOI":"10.1111\/ctr.13265","article-title":"Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia","volume":"32","year":"2018","journal-title":"Clin Transplant"},{"key":"bib16-20230822","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ctr.12361","article-title":"The incidence, management, and evolution of rapamycin-related side effects in kidney transplant recipients","volume":"28","year":"2014","journal-title":"Clin Transplant"},{"key":"bib17-20230822","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17425255.2017.1239708","article-title":"mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions","volume":"13","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"bib18-20230822","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"bib20-20230822","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review","volume":"27","year":"2014","journal-title":"Transpl Int"},{"key":"bib21-20230822","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MPA.0000000000000958","article-title":"Simultaneous pancreas and kidney transplantation is associated with inferior long-term outcomes in African Americans","volume":"47","year":"2018","journal-title":"Pancreas"},{"key":"bib22-20230822","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/imm.12162","article-title":"The mTOR pathway and integrating immune regulation","volume":"140","year":"2013","journal-title":"Immunology"},{"key":"bib23-20230822","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","year":"2015","journal-title":"Drug Discov Today"},{"key":"bib24-20230822","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/MPA.0000000000000428","article-title":"Everolimus improves microcirculatory derangements in experimental postischemic pancreatitis modulating the expression of vascular endothelial growth factor, interleukin 6, and toll-like receptor 4","volume":"44","year":"2015","journal-title":"Pancreas"},{"key":"bib25-20230822","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MOT.0b013e32835c6f0f","article-title":"Risk factors for and management of graft pancreatitis","volume":"18","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"bib26-20230822","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOT.0b013e32835c51b5","article-title":"Immunological monitoring after pancreas transplantation","volume":"18","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"bib27-20230822","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","year":"2004","journal-title":"Am J Transplant"},{"key":"bib28-20230822","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","year":"2011","journal-title":"JAMA"},{"key":"bib29-20230822","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/ajt.13018","article-title":"Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib30-20230822","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1600-6143.2008.02196.x","article-title":"Malignancy after heart transplantation: incidence, prognosis and risk factors","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"bib31-20230822","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","year":"1999","journal-title":"Nature"},{"key":"bib32-20230822","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","year":"2002","journal-title":"Nat Med"},{"key":"bib33-20230822","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.26323","article-title":"The mTOR pathway in hepatic malignancies","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"bib34-20230822","first-page":"i11","article-title":"The role of proliferation signal inhibitors in post-transplant malignancies","volume":"22 Suppl 1","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"bib35-20230822","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib36-20230822","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9 Suppl 3","year":"2009","journal-title":"Am J Transplant"},{"key":"bib37-20230822","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/jlts.2001.24645","article-title":"mTOR inhibitors: an overview","volume":"7","year":"2001","journal-title":"Liver Transpl"},{"key":"bib38-20230822","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-200464080-00005","article-title":"Everolimus","volume":"64","year":"2004","journal-title":"Drugs"},{"key":"bib39-20230822","first-page":"ra75","article-title":"mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells","volume":"2","year":"2009","journal-title":"Sci Signal"},{"key":"bib40-20230822","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","year":"2014","journal-title":"Trends Cell Biol"},{"key":"bib41-20230822","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/acel.12194","article-title":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","volume":"13","year":"2014","journal-title":"Aging Cell"},{"key":"bib42-20230822","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/TP.0000000000001902","article-title":"Rapamycin prolongs graft survival and induces CD4+IFN-\u03b3+IL-10+ regulatory type 1 cells in old recipient mice","volume":"102","year":"2018","journal-title":"Transplantation"},{"key":"bib43-20230822","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","article-title":"Trends in organ donation and transplantation in the United States, 1999\u20132008","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"bib44-20230822","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0966-3274(02)00058-8","article-title":"Rejection and recipient age","volume":"10","year":"2002","journal-title":"Transpl Immunol"},{"key":"bib45-20230822","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trre.2013.03.001","article-title":"Immunosenescence and organ transplantation","volume":"27","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"bib46-20230822","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/01.TP.0000438026.03958.7b","article-title":"Recipient age and risk for mortality after kidney transplantation in England","volume":"97","year":"2014","journal-title":"Transplantation"},{"key":"bib47-20230822","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ctr.12151","article-title":"Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience","volume":"27","year":"2013","journal-title":"Clin Transplant"},{"key":"bib48-20230822","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.TP.0000156165.83160.09","article-title":"Polyomavirus associated-nephropathy in renal transplantation: interdisciplinary analyses and recommendations","volume":"79","year":"2005","journal-title":"Transplantation"},{"key":"bib49-20230822","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","year":"2015","journal-title":"Am J Transplant"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006676-201905000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:01:48Z","timestamp":1785855708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201905000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001322","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}